Kapil Dhingra's most recent trade in Replimune Group Inc was a trade of 3,169 Stock Option (right to buy) done . Disclosure was reported to the exchange on Dec. 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Replimune Grp Inc | Kapil Dhingra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2025 | 3,169 | 0 | - | - | Stock Option (right to buy) | |
| Replimune Grp Inc | Kapil Dhingra | Director | Sale of securities on an exchange or to another person at price $ 10.40 per share. | 09 Dec 2025 | 3,169 | 0 (0%) | 0% | 10.4 | 32,958 | Common Stock |
| Replimune Grp Inc | Kapil Dhingra | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.75 per share. | 09 Dec 2025 | 3,169 | 3,169 (0%) | 0% | 1.8 | 5,546 | Common Stock |
| LAVA Therapeutics NV | Kapil Dhingra | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 33,390 | 0 | - | - | Share Options (Right to Buy) | |
| LAVA Therapeutics NV | Kapil Dhingra | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Nov 2025 | 30,000 | 0 | - | - | Common Shares | |
| CARGO Therapeutics Inc | Kapil Dhingra | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Aug 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 30,550 | 30,550 | - | - | Stock Option (Right to Buy) | |
| Replimune Grp Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 32,000 | 32,000 | - | - | Stock Option (right to buy) | |
| LAVA Therapeutics NV | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 33,390 | 33,390 | - | - | Common Shares (Right to Buy) | |
| Black Diamond Therapeutics Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 30,550 | 30,550 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 11,871 | 11,871 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 49,265 | 49,265 | - | - | Stock Option (Right to Buy) | |
| Replimune Grp Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 32,000 | 32,000 | - | - | Stock Option (right to buy) | |
| Black Diamond Therapeutics Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 16,500 | 16,500 | - | - | Stock Option (Right to Buy) | |
| Replimune Grp Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 25,200 | 25,200 | - | - | Stock Option (right to buy) | |
| Black Diamond Therapeutics Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Replimune Grp Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 16,500 | 16,500 | - | - | Stock Option (right to buy) | |
| Black Diamond Therapeutics Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Replimune Grp Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 16,500 | 16,500 | - | - | Stock Option (right to buy) |